Boring wins in August. While the market chases AI multiples and momentum trades, a quiet cohort of blue-chip dividend compounders continues doing what it has done for decades: raise the payout, return capital, and reward patience. The five names below are all Dividend Kings or Aristocrats with streaks measured in generations, not quarters. Dividend safety leads the thesis here, with each pick backed by cash flow, brand moats, and a fresh raise this year.
Prices and yields referenced below reflect data as of August 14, 2026. Here is the case for each.
Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the anchor of any dependable dividend book. The board raised the quarterly dividend 3.1% to $1.34 per share this spring, marking 64 consecutive years of increases. The next payment lands September 8, 2026, following an August 25 ex-date.
The bull case tightened in Q1 2026, when revenue hit $24.06B (+9.9% YoY) with adjusted EPS of $2.70, beating expectations. Oncology is doing the heavy lifting: DARZALEX at $3.96B (+22.5%), TREMFYA up 68.3%, and CARVYKTI up 62.1%. Shares have delivered 27.2% YTD and 52.73% over one year, a rare growth-plus-yield combination for a stock with a beta of 0.231.
Risk: STELARA biosimilar erosion (-59.7%) is a meaningful revenue headwind, and litigation charges of $330M in Q1 remind investors that legal overhang has not gone away.
Procter & Gamble (PG)
Procter & Gamble (NYSE:PG) owns the longest income record on this list: 70 consecutive years of dividend increases and 136 consecutive years of payments. The current quarterly dividend of $1.0885 supports an annualized forward payout of $4.354, yielding roughly 2.95% at recent prices.
Q4 FY2026 revenue of $21.20B came in light versus the $21.38B estimate, missing expectations, though core EPS of $1.43 beat. Beauty led with 6% Q4 growth, and management is planning roughly $10B in dividends and $5B in buybacks in FY2027. Shares are up 3.08% YTD, an underwhelming showing that arguably makes the entry more attractive.
Risk: A roughly $1B after-tax headwind from commodities, energy, and transportation, plus tariff uncertainty, is pressing on margins. FY2027 organic sales guidance of +1-3% is not exciting.
Coca-Cola (KO)
Coca-Cola (NYSE:KO) just delivered its strongest quarter in years. Q2 2026 revenue of $13.38B (+6.7% YoY) topped the $13.17B estimate, adjusted EPS of $0.97 beat, and global unit case volume grew 5%. Coca-Cola Zero Sugar volumes jumped 16%, and operating margin expanded to 34.9%.
The quarterly dividend stepped up to $0.53 in 2026 from $0.51 in 2025, extending a multi-decade streak. Management raised FY2026 guidance, targeting organic revenue growth of about 5%, comparable EPS growth of 9-10%, and free cash flow near $12.4B. CEO Henrique Braun said the company "delivered another strong quarter." Shares are up 27.15% YTD.
Risk: Asia Pacific price/mix ran -9%, ongoing IRS tax litigation is unresolved, and the fairlife cybersecurity incident lingers as a reputational overhang.
PepsiCo (PEP)
PepsiCo (NASDAQ:PEP) offers the fattest yield in this group at 4.09%, backed by a 54th consecutive annual increase. The Q2 2026 dividend stepped to $1.48 per share from $1.4225, the highest quarterly payout on record. FY2026 cash returns are expected near $8.9B.
Operationally, Q2 revenue reached $24.18B (+6.4% YoY) with organic volume at the fastest pace since 2022. Latin America Foods grew 15% and EMEA 10%. The stock trades at a forward P/E of 16x, cheap for a Dividend King, and is essentially flat YTD at 0.01%. That is the setup patient income investors want.
Risk: Core operating margin narrowed 40bps in Q2, PFNA net revenue declined, and tariff/trade policy remains a wildcard.
McDonald’s (MCD)
McDonald’s (NYSE:MCD) is the contrarian pick here. Shares are down 9.63% YTD, weighed by softer traffic, yet the dividend story remains intact. The quarterly payout stepped to $1.86 in late 2025 from $1.77, keeping the roughly 50-year increase streak alive. About $1.3B was returned via dividends in Q2 alone.
Q2 2026 adjusted EPS of $3.38 beat the $3.32 estimate, and the loyalty program now counts roughly 220M 90-day active users generating more than $40B in trailing systemwide sales. Management is still targeting 50,000 global units by 2028. The analyst target of $316.06 implies meaningful upside from the current $272.83.
Risk: Global comparable sales decelerated to +1.3% from +3.8% a year ago, US guest counts turned negative, and SG&A rose 17%. If traffic weakens further, the multiple compresses before it re-rates.
What to Watch Next
Ex-dividend dates cluster around the back half of August and early September, with JNJ (August 25), MCD (September 1), PEP (September 4), and KO (September 15) all queued up. For income-focused investors positioning into fall, this cohort offers the rare mix of yield, dividend safety, and multi-decade discipline that survives whatever the macro throws at it.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks